Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme
Mohamed Abouelkheir, Tarek H. El‐Metwally
European Journal of Pharmacology (2019) Vol. 862, pp. 172638-172638
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 929
Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations
Awadhesh Kumar Singh, Ritesh Gupta, Amerta Ghosh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 4, pp. 303-310
Open Access | Times Cited: 894
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Inés Valencia, Concepción Peiró, Óscar Lorenzo, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 95
Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
Julio Caballero
Molecules (2020) Vol. 25, Iss. 2, pp. 295-295
Open Access | Times Cited: 51
Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Current Molecular Pharmacology (2021) Vol. 15, Iss. 4, pp. 683-692
Closed Access | Times Cited: 45
Sitagliptin: a potential drug for the treatment of COVID-19?
Sanaa K. Bardaweel, Rima Hajjo, Dima A. Sabbah
Acta Pharmaceutica (2020) Vol. 71, Iss. 2, pp. 175-184
Open Access | Times Cited: 43
DPP4 as a Potential Candidate in Cardiovascular Disease
Siyu Chen, Kong Xiangquan, Ke-Fan Zhang, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 5457-5469
Open Access | Times Cited: 23
Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses
Kannan Sridharan, Gowri Sivaramakrishnan
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Antioxidant and antihypertensive effects of garlic protein and its hydrolysates and the related mechanism
Xudong Gao, Zihan Xue, Qiqi Ma, et al.
Journal of Food Biochemistry (2019) Vol. 44, Iss. 2
Open Access | Times Cited: 36
Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
Upinder Kaur, Kumudini Acharya, Ritwick Mondal, et al.
European Journal of Pharmacology (2020) Vol. 887, pp. 173545-173545
Open Access | Times Cited: 35
Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease
Solomiia Savedchuk, Rasha Raslan, Sarah Nystrom, et al.
Circulation Research (2022) Vol. 130, Iss. 10, pp. 1618-1641
Open Access | Times Cited: 19
Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling
Flavia L. Martins, João Carlos Ribeiro-Silva, Ravi Nistala, et al.
AJP Cell Physiology (2024) Vol. 326, Iss. 4, pp. C1203-C1211
Closed Access | Times Cited: 3
Evaluating Peptides of Picrorhiza kurroa and Their Inhibitory Potential against ACE, DPP-IV, and Oxidative Stress
Shweta Thakur, Jyoti Chhimwal, Robin Joshi, et al.
Journal of Proteome Research (2021) Vol. 20, Iss. 8, pp. 3798-3813
Closed Access | Times Cited: 17
Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)
Katsuhiro Ohyama, Junichiro Shindo, Tomohiro Takahashi, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 12
Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure
Daniel F. Arruda-Junior, Thiago A. Salles, Flavia L. Martins, et al.
Life Sciences (2022) Vol. 305, pp. 120757-120757
Closed Access | Times Cited: 10
The SARS-CoV-2 receptor and other key components of the Renin-Angiotensin-Aldosterone System related to COVID-19 are expressed in enterocytes in larval zebrafish
John H. Postlethwait, Michelle S. Massaquoi, Dylan R. Farnsworth, et al.
Biology Open (2021) Vol. 10, Iss. 3
Open Access | Times Cited: 14
Characterization of Allium tuberosum rottl. Peptides with Dual Inhibitory Activities against Angiotensin I Converting Enzyme and Dipeptidyl Peptidase-IV
Nhung Thi Phuong Nong, Chia-Hui Lee, Jue‐Liang Hsu
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Individual dipeptidyl peptidase‐4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta‐analysis
Satoru Mitsuboshi, Makoto Morizumi, Kazumasa Kotake, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 135, Iss. 1, pp. 71-80
Closed Access | Times Cited: 1
The Roadmap of Plant Antimicrobial Peptides Under Environmental Stress: From Farm to Bedside
Zohreh Ghanbarzadeh, Abdolali Mohagheghzadeh, Shiva Hemmati
Probiotics and Antimicrobial Proteins (2024)
Closed Access | Times Cited: 1
SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
Zemene Demelash Kifle, Alem Endeshaw Woldeyohanin, Chilot Abiyu Demeke
Metabolism Open (2021) Vol. 12, pp. 100134-100134
Open Access | Times Cited: 9
The Molecular Docking and Inhibition Kinetics of Angiotensin I-Converting Enzyme Inhibitory Peptides Derived from Soft-Shelled Turtle Yolk
Nhung Thi Phuong Nong, Christoper Caesar Yudho Sutopo, Wei‐Ting Hung, et al.
Applied Sciences (2022) Vol. 12, Iss. 23, pp. 12340-12340
Open Access | Times Cited: 5
Functional Immune Deficiency Syndrome via Intestinal Infection in COVID-19
Érica T. Prates, Michael R. Garvin, Mirko Pavicic, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 6
Discovery of tight-binding competitive inhibitors of dipeptidyl peptidase IV
Isel Pascual Alonso, Pedro A. Valiente, Mario E. Valdés‐Tresanco, et al.
International Journal of Biological Macromolecules (2021) Vol. 196, pp. 120-130
Closed Access | Times Cited: 5
An intestinal cell type in zebrafish is the nexus for the SARS-CoV-2 receptor and the Renin-Angiotensin-Aldosterone System that contributes to COVID-19 comorbidities
John H. Postlethwait, Dylan R. Farnsworth, Adam C. Miller
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 4
Bioactive peptides: Improving the future of diabetes therapy
Kerem Tok, Hichem Moulahoum, Ebru Kocadağ Kocazorbaz, et al.
Studies in natural products chemistry (2022), pp. 41-74
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top